Dr RR Baliga's "Got Knowledge Doc" Podkast

🚨 Just out in JAMA!

💡 PanEcho, a multitask AI model trained on over 1.2 million echo videos, can automate complete echocardiographic interpretation — from LVEF to valvular disease — with diagnostic AUCs up to 1.00 and MAE as low as 4.2%.

🌍 Validated across international cohorts, including point-of-care settings, this tool could redefine access, accuracy, and efficiency in cardiac imaging.

🫀🤖 A major leap toward AI-assisted cardiovascular diagnostics.

🔗 Read the study

#AIinMedicine #Cardiology #EchoRevolution #PanEcho #DigitalHealth #JAMA #MachineLearning #CardioAI #MedicalImaging #DeepLearning

🚨 New insights from cancer neuroscience! 🧠🧬

A groundbreaking Nature study reveals that cancer cells can steal mitochondria from nearby neurons via tunneling nanotubes — supercharging their metabolism, stemness, and metastatic potential 🌪️💥

Using a clever tool called MitoTRACER, researchers traced this "mitochondrial hijack" across cancers (breast, prostate, melanoma) and showed that recipient cells were more likely to seed distant metastases — especially in the brain 🧳🧠

🧪 Targeting this nerve–tumor energy axis may open new doors to stop metastasis in its tracks 🛑🛤️

#CancerResearch #Neuroscience #Metastasis #Mitochondria #Innovation #NaturePaper #Oncology #TumorMicroenvironment #Stemness #CellBiology #MedicalBreakthrough

🧠💓 Cognitive decline and cardiovascular disease often go hand in hand — but they don't have to spiral together.

In our latest breakdown, we explore how cardiologists can detect, manage, and even improve cognitive impairment through smart risk factor control, lifestyle changes, and a multidisciplinary approach. From MoCA to memantine, TAVR to team-based care — it's time to connect the mind and the heart.

📊 Evidence-based strategies

🩺 Practical tools for clinicians

💡 Insights from JACC's state-of-the-art review

👉 Let's build heart-smart, brain-friendly care — together. #Cardiology #CognitiveHealth #Geriatrics #HeartBrainConnection

🧠💉 Can vaccines protect the mind? New research suggests that AS01-adjuvanted vaccines like Shingrix and Arexvy may reduce the risk of dementia—possibly by stimulating immune pathways like IFN-γ and TLR4, not just by preventing infection.

📊 In a large US-based EHR study, those who received the RSV or shingles vaccine had a significantly lower 18-month dementia risk than flu-vaccinated peers.

🔬 The common thread? The AS01 adjuvant.

🛡️ Could this be a new frontier in neuroprotection? Let's discuss. #Vaccines #Dementia #RSV #AS01 #Neuroimmunology #PublicHealth #Alzheimers #PrecisionMedicine

New Insights from the DanGer Shock Trial! 🫀💡

Can early left ventricular unloading with a microaxial flow pump (mAFP) save lives in STEMI-related cardiogenic shock?

This compelling substudy shows that mAFP not only boosts cardiac output and power, but also reduces pulmonary pressures—all while using less pharmacologic support. 📉💊

🧪 Native CO improved steadily over 48 hours, hinting at myocardial recovery.

📊 PAC data gives us a front-row seat to the physiology behind the survival curves.

🔬 The editorial dives deeper: timing, technique, and future questions.

👉 Time to rethink shock care? Dive in.

#Cardiology #STEMI #CardiogenicShock #CriticalCare #mAFP #PAC #Impella #HeartFailure #DanGerShock #LVUnloading #MechanicalSupport #JACC 🩺📉🫁

🚨 New Breakthrough in Type 2 Diabetes Care! 💊🧬

The ACHIEVE-1 trial shows that Orforglipron, a once-daily oral, nonpeptide GLP-1 receptor agonist, delivers significant reductions in HbA1c and body weight—without injections and with minimal restrictions! 🌍📉

👨‍⚕️ 559 patients across 5 countries

⏱️ 40 weeks, 3 dosing arms (3, 12, 36 mg)

📊 HbA1c ↓ by up to 1.48%, weight ↓ up to 7.6%

✅ No severe hypoglycemia

📌 Mild GI side effects during dose titration

This is a potential gamechanger for early T2DM care—simple, effective, and patient-friendly. 🚀

#Type2Diabetes #GLP1 #Orforglipron #Endocrinology #ClinicalTrials #PrecisionMedicine #Innovation #NEJM #ACHIEVE1 #OralTherapeutics 💥

🚨 Frailty matters — even in the cath lab! 🧓🫀

A new NCDR registry analysis of 1.3M+ older adults shows a clear gradient: as frailty increases, so do complications, mortality, and procedural risks during PCI. Severely frail patients faced a striking 20.3% in-hospital mortality and >50% mortality with cardiogenic shock.

🧠 It's time to treat frailty as a vital sign — embedded in our workflow, guiding shared decisions, and shaping post-PCI care.

📊 Let's bring team-based, geriatric-informed strategies to the forefront of interventional cardiology.

#Cardiology #Frailty #PCI #PrecisionMedicine #AgingWell #GeriatricCardiology #NCDR #HealthcareInnovation #PatientCenteredCare

🚨 Major breakthrough in obesity pharmacotherapy!

The REDEFINE-1 & REDEFINE-2 trials show that once-weekly CagriSema (Cagrilintide + Semaglutide) delivers up to 20% weight loss in people with obesity—and significant glycemic improvements in those with type 2 diabetes. 💉📉

🌍 Global, double-blind RCTs

⚖️ >90% lost ≥5% body weight

🩺 SBP ↓, QoL ↑, prediabetes reversed in 88%

⚠️ GI side effects common but mostly mild

💡 CagriSema is redefining the weight loss frontier—with dual satiety and metabolic action.

#Obesity #GLP1 #Cagrilintide #Semaglutide #CagriSema #WeightLoss #RCT #MetabolicHealth #Prediabetes #NovoNordisk #Endocrinology #InternalMedicine #PrecisionMedicine #Pharma #ClinicalTrials #ObesityMedicine #Amylin #GLP1Agonist #T2D #LifestyleMedicine

🔥 New Study Alert! 🩺

Wildfire smoke isn't just a respiratory threat — it's taking a toll on the heart, especially in older adults.

📊 A nationwide Medicare cohort (~22M) shows that long-term exposure to wildfire-specific PM2.5 is linked to significantly higher heart failure risk — more so than urban pollution.

📍 Vulnerable groups — women, Medicaid-eligible individuals, and low-income communities — face the highest burden.

🌫️ Tiny particles. Massive impact.

📚 Read the study: Hao et al, JACC July 2025

#Cardiology #AirPollution #WildfireSmoke #HeartFailure #EnvironmentalJustice #PM25 #PublicHealth #Epidemiology

🧠💊 Appetite Meets Its Match: The Amylin Advantage"

In this episode of Got Knowledge Doc, we explore how amylin, the lesser-known hormone co-secreted with insulin, is making a comeback — this time as part of a dual receptor strategy with GLP-1.

💡 Learn how amylin:

• 🧠 Activates brainstem satiety centers

• ⏳ Delays gastric emptying

• 📉 Suppresses glucagon

• 🔁 Synergizes with GLP-1 & leptin

We break down the science behind amycretin, the first oral dual GLP-1/amylin agonist, and what it could mean for the future of obesity and metabolic care.